Will U.S. try to circumvent drug firms patent?
:
The furor over Abbott Laboratories’ 400 percent price increase last December of the AIDS drug Norvir has resulted in an unprecedented meeting at the National Institutes of Health to consider circumventing the drug giant’s patent.